Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,823 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,089 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05002270 | JAB-21822 Activity in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation | completed | Phase 1 / Phase 2 | 29 | Jacobio Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Jan 13, 2026 | clinicaltrials |
| NCT05156866 | First in Human Study of TORL-2-307-ADC in Participants With Advanced Cancer | active not recruiting | Phase 1 | 163 | TORL Biotherapeutics, LLCINDUSTRY | 2 | Jan 13, 2026 | clinicaltrials |
| NCT05651022 | Study of DECOY20 With or Without Tislelizumab in Patients With Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 120 | Indaptus Therapeutics, IncINDUSTRY | 1 | Jan 13, 2026 | clinicaltrials |
| NCT03829254 | A Safety, Pharmacokinetic and Clinical Activity Study of NUC-7738 in Patients With Advanced Solid Tumours and Lymphoma | recruiting | Phase 1 / Phase 2 | 135 | NuCana plcOTHER | 1 | Jan 12, 2026 | clinicaltrials |
| NCT04260802 | A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers | terminated | Phase 1 / Phase 2 | 73 | Ocellaris Pharma, Inc.INDUSTRY | 1 | Jan 12, 2026 | clinicaltrials |
| NCT05544552 | Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations(SURF301) | active not recruiting | Phase 1 / Phase 2 | 310 | Tyra Biosciences, IncINDUSTRY | 4 | Jan 12, 2026 | clinicaltrials |
| NCT07312903 | DPTX3186 in Wnt Pathway Activated Solid Tumors | recruiting | Phase 1 | 40 | Dewpoint TherapeuticsINDUSTRY | 1 | Jan 12, 2026 | clinicaltrials |
| NCT05490472 | JAB-2485 Activity in Adult Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 102 | Jacobio Pharmaceuticals Co., Ltd.INDUSTRY | 2 | Jan 9, 2026 | clinicaltrials |
| NCT06737731 | A Phase I/II Clinical Study of SHR-1681 for Injection in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 300 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Jan 9, 2026 | clinicaltrials |
| NCT04284488 | Dose-escalation Study of APG-1387 and Toripalimab in Solid Tumors | terminated | Phase 1 / Phase 2 | 40 | Ascentage Pharma Group Inc.INDUSTRY | 1 | Jan 8, 2026 | clinicaltrials |
| NCT06265727 | A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors | recruiting | Phase 1 / Phase 2 | 348 | Corbus Pharmaceuticals Inc.INDUSTRY | 7 | Jan 8, 2026 | clinicaltrials |
| NCT06631079 | Personalised Neoantigen-targeting Cancer Vaccine NECVAX-NEO1 in Anti-PD-1/PD-L1 Therapy in Patients With Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 20 | NEC Bio B.VINDUSTRY | 3 | Jan 8, 2026 | clinicaltrials |
| NCT06990464 | A Clinical Trial of SIBP-A19 Injection in the Treatment of Advanced Malignant Solid Tumor Patients | recruiting | Phase 1 | 156 | Shanghai Institute Of Biological ProductsINDUSTRY | 1 | Jan 8, 2026 | clinicaltrials |
| NCT07131202 | A Study of FL115 in Combination With a PD-1 Antibody in Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 130 | Suzhou Forlong Biotechnology Co., LtdINDUSTRY | 1 | Jan 8, 2026 | clinicaltrials |
| NCT07327294 | A Phase I/II Study to Evaluate XNW34017 in Patients With Advanced or Metastatic Solid Tumor | not yet recruiting | Phase 1 / Phase 2 | 150 | Evopoint Biosciences Inc.INDUSTRY | 1 | Jan 8, 2026 | clinicaltrials |
| NCT03746431 | A Phase 1 Study of [225Ac]-FPI-1434 Injection | terminated | Phase 1 | 78 | Fusion Pharmaceuticals Inc.INDUSTRY | 3 | Jan 7, 2026 | clinicaltrials |
| NCT03905148 | Study of the Safety and Pharmacokinetics of BGB-283 (Lifirafenib) and PD-0325901 (Mirdametinib) in Participants With Advanced or Refractory Solid Tumors | completed | Phase 1 | 91 | BeiGeneINDUSTRY | 2 | Jan 7, 2026 | clinicaltrials |
| NCT04175847 | A Phase I /IIa Study of RC88-ADC in Subjects With Advanced Malignant Solid Tumors | completed | Phase 1 / Phase 2 | 198 | RemeGen Co., Ltd.INDUSTRY | 1 | Jan 7, 2026 | clinicaltrials |
| NCT06235437 | Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ASD141 | recruiting | Phase 1 | 21 | Ascendo Biotechnology Co., Ltd.INDUSTRY | 1 | Jan 7, 2026 | clinicaltrials |
| NCT06298058 | A Clinical Trial of SIBP-A13 Injection in the Treatment of Advanced Malignant Solid Tumor Patients. | recruiting | Phase 1 | 144 | Shanghai Institute Of Biological ProductsINDUSTRY | 1 | Jan 7, 2026 | clinicaltrials |
| NCT06512116 | A Clinical Trial of SIBP-A17 Injection in the Treatment of Advanced Solid Tumor Patients. | recruiting | Phase 1 | 196 | Shanghai Institute Of Biological ProductsINDUSTRY | 1 | Jan 7, 2026 | clinicaltrials |
| NCT07232407 | A Study of Lutetium [177Lu] BL-ARC001 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid Tumors | recruiting | Phase 1 | 22 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jan 7, 2026 | clinicaltrials |
| NCT04617314 | A Study of RC108-ADC in Subjects With Advanced Malignant Solid Tumors | completed | Phase 1 | 67 | RemeGen Co., Ltd.INDUSTRY | 1 | Jan 6, 2026 | clinicaltrials |
| NCT05174585 | JAB-BX102 Monotherapy and Combination With Pembrolizumab in Adult Patients With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 21 | Jacobio Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Jan 6, 2026 | clinicaltrials |
| NCT05378737 | Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of BAT8006 for Injection | completed | Phase 1 | 216 | Bio-Thera SolutionsINDUSTRY | 1 | Jan 6, 2026 | clinicaltrials |
| NCT05774873 | The Primary Objective of This Study to Evaluate the Safety and Tolerability of IBI334 and Determine the Maximum Tolerated Dose (MTD) and the Recommended Phase 2 Dose (RP2D)and Anti Tumor Activity of IBI334. | completed | Phase 1 / Phase 2 | 28 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Jan 6, 2026 | clinicaltrials |
| NCT07071909 | Immune Reconstitution Monitoring and Pneumococcal Vaccination in Patients Treated With CAR-T Cells | withdrawn | Phase 1 / Phase 2 | 0 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Jan 6, 2026 | clinicaltrials |
| NCT07274852 | A Study of Lutetium [177Lu]-BL-ARC001 in Patients With Locally Advanced or Metastatic Lung Cancer, Breast Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors | recruiting | Phase 1 | 22 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jan 6, 2026 | clinicaltrials |
| NCT05584800 | Study of ZGGS18 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 222 | Suzhou Zelgen Biopharmaceuticals Co.,LtdINDUSTRY | 1 | Jan 5, 2026 | clinicaltrials |
| NCT05864573 | Study of ZGGS15 in Patients With Advanced Solid Tumors | completed | Phase 1 | 22 | Suzhou Zelgen Biopharmaceuticals Co.,LtdINDUSTRY | 1 | Jan 5, 2026 | clinicaltrials |
| NCT06938880 | Study of ZGGS18 in Combination With ZG005 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 60 | Suzhou Zelgen Biopharmaceuticals Co.,LtdINDUSTRY | 1 | Jan 5, 2026 | clinicaltrials |
| NCT07124117 | A Study Evaluating OBI-902 in Participants With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 147 | OBI Pharma, IncINDUSTRY | 2 | Jan 5, 2026 | clinicaltrials |
| NCT07252414 | GenSci143 in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 180 | Changchun GeneScience Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jan 5, 2026 | clinicaltrials |
| NCT06337630 | A Study on Tuvusertib (Oral ATR Inhibitor) in Combination With PLX038 (Topo1 Inhibitor) in Patients With Advanced Solid Tumors(POP-ART) | terminated | Phase 1 | 10 | Institut CurieOTHER | 1 | Jan 2, 2026 | clinicaltrials |
| NCT07310134 | Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of ZX-8177 in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 80 | Nanjing Zenshine PharmaceuticalsINDUSTRY | 1 | Jan 2, 2026 | clinicaltrials |
| NCT07232524 | A Study of BL-M24D1 in Patients With Locally Advanced or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors | recruiting | Phase 1 | 16 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Dec 31, 2025 | clinicaltrials |
| NCT03993678 | Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With Advanced Solid Tumors. | completed | Phase 1 / Phase 2 | 28 | Swiss Cancer InstituteOTHER | 1 | Dec 30, 2025 | clinicaltrials |
| NCT04648254 | Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor in Patients With Advanced Solid Tumor | completed | Phase 1 | 51 | Qurient Co., Ltd.INDUSTRY | 1 | Dec 30, 2025 | clinicaltrials |
| NCT06198426 | A Study of IBI3004 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors | terminated | Phase 1 / Phase 2 | 5 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 2 | Dec 30, 2025 | clinicaltrials |
| NCT06368921 | A Study of Recombinant Oncolytic Virus M1(VRT106) in Patients With Solid Tumors | recruiting | Phase 1 | 30 | Guangzhou Virotech Pharmaceutical Co., Ltd.INDUSTRY | 1 | Dec 30, 2025 | clinicaltrials |
| NCT06882135 | HW071021 Monotherapy in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 76 | Wuhan Humanwell Innovative Drug Research and Development Center Limited CompanyINDUSTRY | 1 | Dec 29, 2025 | clinicaltrials |
| NCT07100210 | A Clinical Trial Evaluating IL-22BP/LNP Compound in Refractory Malignant Solid Tumors for Safety, Tolerability and Activity | recruiting | Phase 1 | 6 | Xingchen PengOTHER | 1 | Dec 29, 2025 | clinicaltrials |
| NCT07165067 | A Study of AP601 in Patients With Locally Unresectable Advanced or Metastatic Solid Tumors | recruiting | Phase 1 | 36 | AP Biosciences Inc.INDUSTRY | 1 | Dec 29, 2025 | clinicaltrials |
| NCT07265622 | First-in-human Study of 7MW4911 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 200 | Mabwell (Shanghai) Bioscience Co., Ltd.INDUSTRY | 1 | Dec 29, 2025 | clinicaltrials |
| NCT07307053 | Rare Tumor Focused Platform Study of Innovative Therapies and Technologies (PLATFORM2) | not yet recruiting | Phase 1 / Phase 2 | 600 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | Dec 29, 2025 | clinicaltrials |
| NCT05025358 | A Study of LP-118 in Patients With Advanced Tumors | completed | Phase 1 | 68 | Guangzhou Lupeng Pharmaceutical Company LTD.INDUSTRY | 1 | Dec 26, 2025 | clinicaltrials |
| NCT06022029 | A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.(ON-5001) | recruiting | Phase 1 | 168 | OncoNano Medicine, Inc.INDUSTRY | 2 | Dec 24, 2025 | clinicaltrials |
| NCT06328673 | A Study of DM919 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors | active not recruiting | Phase 1 | 160 | D2M Biotherapeutics Inc.INDUSTRY | 2 | Dec 24, 2025 | clinicaltrials |
| NCT06488716 | A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7759065 as a Single Agent and in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Solid Tumors | terminated | Phase 1 | 12 | Genentech, Inc.INDUSTRY | 4 | Dec 24, 2025 | clinicaltrials |
| NCT06626256 | STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Colorectal Cancer, Renal Cell Cancer, Cervical Cancer and Melanoma | withdrawn | Phase 1 | 0 | City of Hope Medical CenterOTHER | 0 | Dec 24, 2025 | clinicaltrials |
Data updated 24 days agoSource updated Jan 13, 2026source: clinicaltrials